Immunomedics (Nasdaq: IMMU) Announces Deal, Shares Pop, and Largest Shareholder Objects

Immunomedics Inc. – Nasdaq: IMMU

Immunomedics, Inc. (Nasdaq: IMMU) is a biopharmaceutical company that specializes in anti-body therapeutics for the treatment of cancer, auto-immune disorders, and other serious diseases. Shares responded favorably to the company’s earnings statement on February 9, 2017 – ending up about 3% to $4.15. However, IMMU gapped up on Friday’s open to $4.64 and hit a high of $5.89 on news that it has entered an exclusive global licensing agreement with Seattle Genetics, Inc. (Nasdaq: SGEN), an innovative global biotechnology company that develops and commercializes novel antibody-drug conjugates (ADCs) for the treatment of cancer. Under the agreement, Seattle Genetics (Nasdaq: SGEN) will develop, fund, manufacture and commercialize IMMU-132, Immunomedics Inc.’s (Nasdaq: IMMU) proprietary solid tumor therapy candidate. IMMU closed Friday trading with over a 20% gain.

Despite the positive reaction from the market, Immunomedics Inc. (Nasdaq:IMMU) largest shareholders, venBio Delect Advisor LLC, released a strongly worded press release criticizing the deal and Immunomedic Inc.’s management:

Immunomedics’ announcement of a deal with Seattle Genetics is a blatant and shameful maneuver by the current Board and management to manipulate the outcome of the upcoming Annual Meeting and entrench themselves at the expense of stockholders’ best interests, and venBio is exploring all options to hold them accountable. The current Board’s attempt to claim that the timing of this partnership – four business days before the Annual Meeting – is coincidental and was motivated purely by a desire to identify the best deal is preposterous and clearly disingenuous, in our view, especially when they have agreed to an aberrantly short six business day go-shop period.”

The press release from New York, NY-based venBio continued: “The bottom line is that what the current Board says cannot be trusted, and their credibility with stockholders has long ago been squandered. The fact that all three proxy advisory firms – ISS, Glass Lewis, and Egan Jones – recommended for our full slate of four nominees, as well as the market’s unenthusiastic reaction to this deal, further demonstrates that this is the case.”

venBio Select Advisor LLC is the SEC registered investment manager for venBio’s public markets strategy and its main equity investment vehicle – the venBio Select Fund – which primarily invests across the biotechnology and therapeutics sector.

IMMU shareholders may have cause to join with venBio’s statement of concern. Immunomedics Inc.’s (Nasdaq: IMMU) financial performance has not been stellar. Sales in 2012 were a reported $32.7 million and have declined to $3.2 million in 2016. EPS for IMMU has seen a similar trajectory. In 2012 IMMU shares had an EPS of $0.02. Since then the trend has been steadily downward and in 2016 IMMU EPS showed a loss of $0.62. Two firms follow Immunomedics Inc. One rates IMMU shares as a “Strong Buy”, while the other rates the shares as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/10/2017
Ticker Symbol IMMU
Last Price a/o 7:58 PM EST  $                      5.22
Average Volume                1,890,000
Market Cap (mlns)  $                  557.83
Sales (mlns) $3.20
Shares Outstanding (mlns) 106.66
Share Float (mlns) 99.57
Shortable Yes
Optionable Yes
Inside Ownership 3.20%
Short Float 23.37%
Short Interest Ratio 12.34
Quarterly Return 117.92%
YTD Return 42.51%
Year Return 157.64%

Biocept, Inc. (Nasdaq: BIOC) Shares Respond Aggressively to News

Biocept, Inc. – Nasdaq: BIOC

Biocept Inc. shares are up over 50% in Friday’s pre-market trading from Wednesday’s close on news that Biocept Inc. has agreed to a group purchasing agreement with a national health plan that establishes pricing for its members for Biocept Inc.’s liquid biopsy tests. Over 17 million shares of BIOC, traded on the Nasdaq, changed hands Thursday – average daily volumes had been just over 2 million.

Biocept Inc. is a cancer diagnostics company that utilizes blood samples, rather than traditional, expensive, and invasive biopsies, to provide information on solid tumor indications to physicians that enable them to select personalized treatment for cancer victims. The San Diego, CA-based company sells its kits directly to physicians, group practices, cancer treatment centers, and hospitals based in the USA.

Last month, BIOC shares jumped over 75% ($1.81) on news that the firm had successfully negotiated an in-network provider agreement with BlueCross-BlueShield of Texas – the state’s largest provider of health care benefits. Shares continued to rise and within a few days were almost three times the value ($2.71) of the stock Pre-BCBS announcement. By February 2, however, BIOC had retreated to $1.39. Since then, shares have climbed back and are trading around $1 higher ($2.38). Clearly, the market responds aggressively to news surrounding Biocept Inc.

Interestingly, the analysts’ consensus price target for BIOC is $1.58 – about $1 less than current trading levels. However, only two firms cover Biocept Inc. with one rating BIOC as a “Strong Buy” and the other rating the shares a “Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/10/2017
Ticker Symbol BIOC
Last Price a/o 8:00 AM EST  $                      2.57
Average Volume                2,640,000
Market Cap (mlns)  $                    34.78
Sales (mlns) $2.10
Shares Outstanding (mlns) 15.88
Share Float (mlns) 15.29
Shortable Yes
Optionable Yes
Inside Ownership 2.20%
Short Float 13.69%
Short Interest Ratio 0.79
Quarterly Return 171.31%
YTD Return 182.58%
Year Return 57.55%

Cellect Biotechnology Ltd. (Nasdaq: APOP) Pop Up Over 60%!

Cellect Biotechnology Ltd. – Nasdaq: APOP

Shares of Israeli-based Cellect Biotechnology rose over 60% in today’s trading on volumes 35 times greater than its daily averages. APOP, traded on the Nasdaq, settled yesterday at $4.17 and rose to $6.77 today before settling back below $5. APOP shares broke higher on news that Cellect had treated its first blood cancer patient in its Phase I/II clinical trial of its stem cell technology ApoGraft.

Small-cap Cellect Biotechnology has developed a breakthrough technology for the selection of stem cells from any given tissue for any clinical indication; a technology that aims to enable a variety of stem cells applications. The Company’s technology is expected to provide pharma companies, medical research and hospitals with the tools to rapidly produce stem cells in quantity and quality that will enable commercialization of all stems cell based treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cells related treatments in regenerative medicine while this specific clinical trial is aimed at the cancer treatment by bone marrow transplantations.

The current Phase I/II trial is intended to determine the efficacy of ApoGraft in preventing Graft-vs-Host disease (GvHD) which is reported to be a common complication associated with stem cell transplants. GvHD occurs when the transplanted immune stem cells attack the recipients body cells and organs. GvHD is considered a life-threatening condition and is seen in up to 50% of stem cell transplants. In this specific trial, the tested stem cells are being transplanted from a matched donor who is related to the patient.

Cellect CEO, Shai Yarkoni commented, “Enrolling our first cancer patient to be treated using our groundbreaking method is a critical milestone for millions of patients worldwide. ApoGraft™ has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies. I am excited with prospects of Cellect becoming a key contributor to the fast-growing market for stem cells based products enabling 21st century regenerative medicine.”

Investors should view APOP with some trepidation. Financial reports disclose a low cash position and it is common for biotech firms to raise cash through secondary stock offerings that would dilute any holdings. Cellect Biotechnology has no reported sales and APOP shares are rated as a “Strong Buy” by the only firm that covers it.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/8/2017
Ticker Symbol APOP
Last Price a/o 2:24 PM EST  $                      4.82
Average Volume                    151,500
Market Cap (mlns)  $                  448.62
Sales (mlns)
Shares Outstanding (mlns) 107.58
Share Float (mlns) 3.14
Shortable Yes
Optionable No
Inside Ownership 0.00%
Short Float 0.28%
Short Interest Ratio 0.06
Quarterly Return 1.71%
YTD Return 34.95%
Year Return 0.00%

MYOS RENS Technology (Nasdaq: MYOS) to Close on Direct Offering Today

MYOS RENS Technology Inc. – Nasdaq: MYOS

Last Friday shares of MYOS RENS Technology, a bionutrition and biotherapeutics company, gained over 37% on over 150 times the previous day’s volumes. This week MYOS shares, traded on the Nasdaq, have increased over 30% on heavy volumes – ending the after-hours session at $4.80.

Today the closing of the registered direct offering is expected to take place. The Company entered a securities purchase agreement with an investor, announced on February 3, 2017, to sell 500,000 shares of its common stock at a per share price of $4.25. The Company intends to use the net proceeds for general corporate purposes.

Cedar Knolls, NJ-based MYOS RENS Technology is also known as “the muscle company”. MYOS develops and commercializes products that improve muscle health and performance. MYOS is the owner of Fortetropin®, the world’s first clinically demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery.

Dr. Robert Hariri, U.S. Chairman of MYOS RENS Technology stated in a January 30, 2017 press release “It has become clear that myostatin is a key clinical target to address fundamental issues such as sarcopenia, inflammation and aging. MYOS RENS continues to lead in the development of products that target myostatin, and we believe, is the only company that has a safe and effective product on the market to modulate myostatin.”

Shareholders of nano-cap MYOS have experienced EPS losses since 2011 when MYOS posted a loss of $4.54. EPS losses continued for the next several years and in 2015 the loss narrowed to $1.64. Sales have been erratic. In 2010 MYOS reported a figure of $100k, followed by figures of $$900k, $3.3 million, $3.3 million, and just $200k in 2015.

Of note is that famed astronaut Dr. Buzz Aldrin is a paid member of MYOS’ Board of Directors and the company spokesperson.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/8/2017
Ticker Symbol MYOS
Last Price a/o 9:30 AM EST  $                      4.37
Average Volume                1,180,000
Market Cap (mlns)  $                    17.46
Sales (mlns) $0.30
Shares Outstanding (mlns) 3.7
Share Float (mlns) 2.48
Shortable Yes
Optionable No
Inside Ownership 10.80%
Short Float 1.78%
Short Interest Ratio 0.04
Quarterly Return 225.07%
YTD Return 300.00%
Year Return 214.67%

Second Sight Medical Products (Nasdaq: EYES) Rockets on Offering

Second Sight Medical Products Inc. – Nasdaq: EYES

Shares of Second Sight Medical Products Inc (Nasdaq: EYES) traded twenty times their average daily volume on Tuesday. EYES shares closed Monday at $1.55, closed Tuesday’s regular session up 78% at $2.76, then dropped 11.5% in after-hours trading to end at $2.44.

Second Sight had announced that it had set 5PM, Feb. 10, 2017, as the cut-off date for a rights offering. Second Sight intends to issue non-transferable subscription rights to purchase units, composed of a share of Second Sight common stock and a five-year warrant to purchase an additional share of common stock, to holders of Second Sight’s common stock on the record date. The subscription rights will expire if they are not exercised by 5:00 p.m. Eastern Time on March 6, 2017. Second Sight may, in its sole discretion, extend the rights offering for additional periods and may cancel the rights offering at any time or for any reason prior to the expiration date.

Each right will entitle the holder to invest $0.47 toward the purchase of units, each such unit, composed of one share of common stock and a warrant to purchase common stock, at a subscription price that is the lesser of $2.00 or the closing price per share of our common stock on Nasdaq on March 6, 2017, the close of the subscription period. The five-year warrant will entitle the holder to purchase one share of common stock, at an exercise price that is equal to the subscription price from the date of issuance through the warrant expiration date.

Sylmar, CA-based Second Sight Medical Products, Inc. develops, manufactures, and markets implantable prosthetic devices to restore functional vision to the blind. The company’s product called “Argus II” works by gathering imagery from a camera built into a pair of glasses worn by the patient. For people that have become blind due to optic nerve damage, Second Sight is moving forward with Orion I – a device that sends signals from the eye implant directly to the cerebral cortex – diverting around the retina. Orion I is rumored to have a much broader application to the medical field and results are awaited with great anticipation.

On February 2, 2017 EYES shares rose 4% after news was announced that the German regulators have renewed Status 1 reimbursement for its Argus II Retinal Prosthesis system. Under Germany’s NUB innovation program, 15 designated hospitals can negotiate reimbursement coverage for the device in patients with advanced retinitis pigmentosa.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/7/2017
Ticker Symbol EYES
Last Price a/o 8:00 PM EST  $                      2.44
Average Volume                    448,480
Market Cap (mlns)  $                  113.57
Sales (mlns) $5.60
Shares Outstanding (mlns) 41.15
Share Float (mlns) 24.75
Shortable Yes
Optionable Yes
Inside Ownership 0.60%
Short Float 13.29%
Short Interest Ratio 7.33
Quarterly Return 41.54%
YTD Return 40.10%
Year Return -33.17%

Galena Biopharma (Nasdaq: GALE) Shares Reflect the Drama

Galena Biopharma, Inc. – Nasdaq: GALE

Shares of biotech company Galena Biopharma have averaged less than 2 million shares traded daily. Yesterday over 32 million shares traded hands and GALE, traded on the Nasdaq, gained 17.5% as they settled at $1.41. However, it should be noted that GALE reached a high of $2.41 earlier in the day before steadily dropping to the eventual settlement price.

The market was reacting to news that Galena’s drug candidate NeuVax, an experimental breast cancer vaccine, was given a green light to continue its trials after a panel of experts claimed that there were no safety concerns that would justify the trial’s stoppage. The trials are determining if NeuVax, in combination with Roche’s Herceptin, can impede the recurrence of breast cancer. This result marked a turn-around for NeuVax’s fortunes. Last year a committee expressed deep reservations of the drug’s efficacy and many thought that was the end of NeuVax.

Good news has been hard to come by for Galena investors. Shares of GALE dropped over 90% in 2016 and the company was forced to undergo a 1:20 reverse stock split to keep its Nasdaq listing. The biotech company’s marketing of their painkiller Abstral became the focus of an investigation by the New Jersey Attorney’s office and the Justice Department. That led to the firing of CEO Mark Schwartz, rumored to be at the center of the investigation, who had obtained the rights to Abstral in 2013, then sold it in 2015. The investigation centers on rebate agreements and possible charges include mail fraud and bribery.

The board recently hired a firm to evaluate Galena’s strategic alternatives – often used as a euphemism for a sale of the company. A sale may be the only avenue left for the nano-cap biotech. There appears to be enough cash left for only six months of operations but traders quickly point out that Galena’s cash/share is almost $1 above current pricing levels.

The other possible ray of hope is drug GALE-401. A platelet reducer that addresses thrombocythemia and has received FDA approval. Galena’s version of the drug is in clinical trials and rumors are that it will prove successful. But again – can Galena attract enough capital to stay viable and market the drug? If they can pull it off, look for GALE shares to rocket. If they can’t, Galena may not be around to watch the July 4th fireworks.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/7/2017
Ticker Symbol GALE
Last Price a/o 8:44 AM EST  $                      1.43
Average Volume                1,800,000
Market Cap (mlns)  $                    14.34
Sales (mlns)
Shares Outstanding (mlns) 10.17
Share Float (mlns) 10.17
Shortable Yes
Optionable Yes
Inside Ownership 0.30%
Short Float 19.06%
Short Interest Ratio 1.08
Quarterly Return -60.83%
YTD Return -27.32%
Year Return -88.81%

Aratana Therapeutics (Nasdaq: PETX) Delays Launch and Shares Plummet

Aratana Therapeutics, Inc. – Nasdaq: PETX

Aratana Therapeutics Inc. announced that its Entyce product (capromorelin oral solution), approved in May of 2016 by the FDA’s Center for Veterinary Medicine, will not be hit the market until late 2017. Entyce is an oral liquid approved to treat dogs who have lost their desire to eat, a condition affecting ten million canines annually. The announcement sent its shares, traded on the Nasdaq under ticker PETX, sliding over 18% in early trading on heavy volumes. PETX ended Friday’s session at $8.03 and gapped down to open at $7.23 as traders reacted to the announcement of the delay.

Leawood, KS-based Aratana Therapeutics is a clinical-stage biopharmaceutical company. Aratana develops, licenses, and markets pet therapeutics for dogs and cats. The stated vision of Aratana is to find human drug development opportunities and apply them to veterinary medicine, specifically to advance therapeutics for pets. Aratana believes there is a gap in the availability of innovative treatments for serious diseases or chronic conditions in dogs and cats when compared to the market for humans – they claim that development typically lags years behind human health.

Rumors abound that Aratana is a possible acquisition after the Mars Incorporated acquired Aratana Therapeutics competitor VCA Antech (Nasdaq: WOOF) for $8 billion. Mars could be now receiving more than half its revenues from pet related sales. This continues a trend that reflects the fact that the average family size is shrinking while spending for pets continues its steady growth – pet healthcare expenditures have risen around 20% in just over two years.

PETX is trading at over three times its normal average daily volume in early morning action. Analysts from five firms follow PETX shares. Four rate PETX as a “Strong Buy” and one rates the shares as a “Hold”. Their consensus price target is $11.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/6/2017
Ticker Symbol PETX
Last Price a/o 10:24 AM EST  $                      6.64
Average Volume                    412,220
Market Cap (mlns)  $                  292.69
Sales (mlns) $38.30
Shares Outstanding (mlns) 36.45
Share Float (mlns) 35.32
Shortable Yes
Optionable Yes
Inside Ownership 2.60%
Short Float 8.77%
Short Interest Ratio 7.52
Quarterly Return 1.90%
YTD Return 11.84%
Year Return 123.68%

Actinium Pharmaceuticals (NYSE: ATNM) Jumps Over 30% on Massive Volumes

Actinium Pharmaceuticals Inc. – NYSE: ATNM

Actinium Pharmaceuticals gained over 30% in today’s trading on exceptionally heavy volumes. ATNM, traded on the NYSE, has an average daily volume of 275k, but today over 5.5 million shares traded hands.

New York, NY-based Actinium Pharmaceuticals is a biotech company that develops innovative targeted payload immunotherapies for the treatment of advanced cancers. The Company’s radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target.

Actinium’s lead product is Iomab-B and is in its crucial Phase 3 clinical trial. Iomab-B is a myeloablative therapy, designed to destroy a patient’s bone marrow so that a patient can receive bone marrow from a donor via a transplant. Also in Actiniumn’s pipeline is its Alpha Particle Immunotherapy (APIT) platform. Being 100 times more powerful than beta particles, alpha therapy is effective in cancers that are not sensitive to beta irradiation such as victims of Acute Myeloid Leukemia (AML). AML treatment utilizing APIT has demonstrated extremely high cancer cell kill levels.

On January 27 – 28, 2017, in Dallas, TX, Chief Medical Officer, Dr. Mark Berger will present at the 3rd Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dava Oncology is sponsoring the event as part of their Oncology Meeting Innovations program. Dr. Berger’s talk will focus on Actinium’s Iomab-B.

ATNM shares took a 20% dive in September when the company announced a public offering of an additional 8 million shares at $1.25 a piece plus offering the underwriters a 30-day option on an additional 15% of the sold stock. The price gapped down to below $1.40 and broke the $1 barrier in late October. Shares rebounded slightly and traded around the $1 handle until today when the stock took off and closed at $1.36 – just two cents short of the daily high.

Actinium Pharmaceuticals has yet to post any sales but institutions own over 10% of its shares – a fact which comforts some investors. ATNM had its largest earnings loss in 2012 when the company announced a loss of $7.58 per share. Earnings have never been positive; the last three years have seen per share losses under $1 with 2015 posting a loss of $0.55. Two firms follow Actinium Pharmaceuticals and both rate ATNM shares as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol ATNM
Last Price a/o 3:59 PM EST  $                      1.36
Average Volume                    274,270
Market Cap (mlns)  $                    57.42
Sales (mlns)
Shares Outstanding (mlns) 55.75
Share Float (mlns) 51.06
Shortable Yes
Optionable Yes
Inside Ownership 8.50%
Short Float 2.31%
Short Interest Ratio 4.3
Quarterly Return 4.99%
YTD Return 17.17%
Year Return -50.00%

Pulmatrix, Inc. (Nasdaq: PULM) Resting After Massive Gains

Pulmatrix, Inc. – Nasdaq: PULM

Pulmatrix shares have had quite a ride recently. In mid-January PULM, traded on the Nasdaq, were traing below $1. Yesterday they traded over $6 and are now down to $4.87 in early trading on volumes near 10 million – average daily volume is just under three million.

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Three days ago the company announced that it has entered into a definitive agreement with institutional investors to purchase approximately $5.0 million of shares of common stock in a registered direct offering. That temporarily halted the stock’s rapid rise on dilution worries.

Pulmatrix first reported sales in 2015 and posted a figure of $1.2 million. Since 2011 PULM shares have experienced negative EPS. In 2014 PULM lost $3.47 per share, and in 2015 the company posted an EPS loss of $3.24. No firms or analysts follow shares of PULM.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol PULM
Last Price a/o 11:12 AM EST  $                    13.26
Average Volume                2,940,000
Market Cap (mlns)  $                    74.92
Sales (mlns) $1.00
Shares Outstanding (mlns) 14.69
Share Float (mlns) 13.19
Shortable No
Optionable No
Inside Ownership 26.44%
Short Float 0.15%
Short Interest Ratio 0.01
Quarterly Return 325.00%
YTD Return 764.41%
Year Return 82.14%

Cerulean Pharma (Nasdaq: CERU) Shares Rise on Sale Speculation

Cerulean Pharma, Inc. – Nasdaq: CERU

An announcement by the Board of Cerulean Pharma to explore strategic alternatives has sent shares higher on speculation that a sale may be in the works. CERU, traded on the Nasdaq under ticker CERU, ended trading Thursday at $0.93 and have reached a high of $1.49 in early trading on heavy volumes. The announcement was likely due to a Phase 2 clinical trial failure, in August, which led to Cerulean cutting half its workforce.

Waltham, MA-based Cerulean Pharma develops products to improve treatment options for cancer victims. The company developed the Dynamic Tumor Targeting™ Platform designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Cerulean’s lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials. Our lead indication is ovarian cancer. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development for the treatment of advanced solid tumors.

Cerulean sales peaked in 2012 when the company posted a figure of $600k. No sales were reported for 2015. CERU shares have never experienced positive EPS – losing more than $1.20 EPS in each of the past five years. CERU lost $1.56 EPS in 2015. Three firms rate CEU shares. One rates them as a “Strong Buy”, and the other rates CERU as a “Hold”. Their consensus price target is $1.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol CERU
Last Price a/o 9:23 AM EST  $                      1.34
Average Volume                    328,570
Market Cap (mlns)  $                    25.49
Sales (mlns)
Shares Outstanding (mlns) 27.38
Share Float (mlns) 24.66
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 2.68%
Short Interest Ratio 2.01
Quarterly Return 24.82%
YTD Return 31.46%
Year Return -58.99%